Skip to main content
Premium Trial:

Request an Annual Quote

Debra Goff, Donna Mildvan, Melissa Miller, Frederick Nolte, Robin Patel

Curetis has established a US scientific advisory board consisting of five infectious disease experts. Debra Goff, Donna Mildvan, Melissa Miller, Frederick Nolte, and Robin Patel will support the clinical adoption of the firm's Unyvero System and lower respiratory tract infection assay recently cleared by the US Food and Drug Administration. 

Goff is currently an infectious diseases specialist with the One Health Antibiotic Stewardship team at The Ohio State University; Mildvan is professor of medicine at Icahn School of Medicine at Mount Sinai in New York; Miller is director of the clinical molecular microbiology laboratory at the University of North Carolina at Chapel Hill School of Medicine; Nolte is medical director of clinical labs and molecular pathology at the Medical University of South Carolina; and Patel is co-director of the clinical bacteriology laboratory, director of the infectious diseases research lab, and chair of the division of clinical microbiology at Mayo Clinic.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.